Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Sjögren’s syndrome
    • Lupus
    • Patient Resources & Advocacy
  • News

Daily Archives: June 23, 2021

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients

NewsBy Development TeamJune 23, 2021

St. Petersburg, FL–June 23, 2021–Resolve Therapeutics, pioneeringfirst–in–class,targeted, safetherapiesfor underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV–132 to initiate a phase 2 clinical trial in patients with long covid.

© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top